Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dihydroergotamine mesilate intranasal - Britannia

Drug Profile

Dihydroergotamine mesilate intranasal - Britannia

Alternative Names: Dihydroergotamine nasal powder - Britannia

Latest Information Update: 19 Jul 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Britannia Pharmaceuticals
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Migraine

Most Recent Events

  • 30 May 2007 Dihydroergotamine-intranasal is still in phase I trials for migraine in the EU
  • 06 Apr 2004 Dihydroergotamine nasal powder for migraine is available for licensing worldwide (http://www.britannia-pharm.co.uk)
  • 26 Feb 2004 Phase-I clinical trials in Migraine in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top